Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET

Company Participants

Marek Ciszewski - Investor Relations

Denny Lanfear - Chief Executive Officer

Theresa Lavallee - Chief Development Officer

Rosh Dias - Chief Medical Officer

Paul Reider - Chief Commercial Officer

McDavid Stilwell - Chief Financial Officer

Conference Call Participants

Robyn Karnauskas - Truist Securities

Salim Syed - Mizuho

Mike Nedelcovych - TD Cowen

Douglas Tsao - H.C. Wainwright

Ash Verma - UBS

Chris Schott - JPM

Operator

Good day and thank you for standing by. Welcome to the Coherus Biosciences Q1 2023 Earnings Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your first speaker, Marek Ciszewski of Investor Relations for Coherus BioSciences. Please go ahead.

Marek Ciszewski

Thank you, Crystal and good afternoon everyone and thank you for joining us. We issued a press release earlier today announcing our financial results for the first quarter of 2023. This release can be found on the Coherus BioSciences website and is also attached to our Form 8-K. Today’s call includes forward-looking statements regarding Coherus’ current expectations about future events. These statements include, but are not limited to, our ability to gain approval for multiple new products and launch them, the ability of the FDA to complete all required inspections in China are our BLA for toripalimab necessary for approval, expectations about demand, timing of our ability to gain market share for any of our approved products, expectations about future revenues and expenses and the timing of any return to profitability. All these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from those implied by forward-looking statements. These statements are not guarantees of future performance and are subject to substantial risks and uncertainties that are discussed in our press release that we issued today as well as the documents that we file with the SEC. Forward-looking statements provided on the call today are made as of this date and we undertake no duty to update or revise any forward-looking statements.

First quarter 2023 results are not necessarily indicative of results for future periods. With me on today’s call are Denny Lanfear, our CEO; Dr. Theresa Lavallee, Chief Development Officer; Dr. Rosh Dias, Chief Medical Officer; Paul Reider, Chief Commercial Officer; and McDavid Stilwell, Chief Financial Officer.